14.2 Obstructive Sleep Apnea Studies in Adults with Obesity Overview of Study 5 and Study 6 The efficacy of ZEPBOUND for moderate to severe obstructive sleep apnea (OSA) (apnea-hypopnea index [AHI] 15) in patients with obesity (BMI 30 kg/m2) was evaluated in a master protocol clinical trial (NCT05412004) that included two randomized, double-blind, placebo-controlled trials (Study 5 and Study 6) of 52 weeks duration
Finally, the translational relevance of the 100 nM dose remains uncertain due to discrepancies with clinical pharmacokinetics, and the clinical safety at this dose under long-term use still needs to be further evaluated
This not only helps patients navigate the process but also demonstrates the clinics commitment to patient care
Since CagriSema already contains semaglutide 2.4 mg, transitioning from standalone semaglutide to CagriSema would theoretically be simpler, though clinical guidance on this transition is limited
He Liang (71) compared the expression of GLP-1R in papillary thyroid cancer tissues and cells before and after GLP-1RA intervention and reported that GLP-1RA had no significant effect on the proliferation of papillary thyroid cancer cells and did not activate the PI3K/AKT or MAPK/ERK signaling pathway
Samimi G, Fink D, Varki NM, Husain A, Hoskins WJ, Alberts DS, et al
